| 85.77 0.94 (1.11%) | 01-20 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 101.69 | 1-year : | 118.78 |
| Resists | First : | 87.06 | Second : | 101.69 |
| Pivot price | 81.24  |
|||
| Supports | First : | 79.67 | Second : | 75.09 |
| MAs | MA(5) : | 84.63 |
MA(20) : | 81.37 |
| MA(100) : | 88.08  |
MA(250) : | 74.76 |
|
| MACD | MACD : | 0.5 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 85.3 |
D(3) : | 81.7 |
| RSI | RSI(14): 58.3 |
|||
| 52-week | High : | 99.5 | Low : | 54.09 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ ANIP ] has closed below upper band by 13.0%. Bollinger Bands are 39.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 86.83 - 87.25 | 87.25 - 87.63 |
| Low: | 82.35 - 82.82 | 82.82 - 83.26 |
| Close: | 85 - 85.74 | 85.74 - 86.43 |
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was incorporated in 2001 and is headquartered in Baudette, Minnesota.
Mon, 19 Jan 2026
ANI Pharmaceuticals, Inc. $ANIP Shares Sold by Mizuho Markets Americas LLC - MarketBeat
Sat, 17 Jan 2026
ANI Pharmaceuticals (ANIP) Is Up 11.2% After Raising 2026 Revenue Outlook And Rare Disease Hiring Plan – Has The Bull Case Changed? - Sahm
Fri, 16 Jan 2026
Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Fri, 16 Jan 2026
ANIP vs. TEVA: Which Drug Stock Is the Better Buy Right Now? - Eastern Progress
Thu, 15 Jan 2026
ANIP Stock Rises 7% in a Week: Here's What You Should Know - Zacks Investment Research
Tue, 13 Jan 2026
ANI Pharmaceuticals (ANIP) Stock Trades Down, Here Is Why - Finviz
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 22 (M) |
| Shares Float | 19 (M) |
| Held by Insiders | 9.9 (%) |
| Held by Institutions | 98.2 (%) |
| Shares Short | 2,960 (K) |
| Shares Short P.Month | 2,850 (K) |
| EPS | 1.6 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 24.19 |
| Profit Margin | 4.9 % |
| Operating Margin | 10.1 % |
| Return on Assets (ttm) | 2.3 % |
| Return on Equity (ttm) | 8.6 % |
| Qtrly Rev. Growth | 53.5 % |
| Gross Profit (p.s.) | 22.36 |
| Sales Per Share | 36.81 |
| EBITDA (p.s.) | 6.34 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 171 (M) |
| Levered Free Cash Flow | 116 (M) |
| PE Ratio | 53.6 |
| PEG Ratio | 0 |
| Price to Book value | 3.54 |
| Price to Sales | 2.32 |
| Price to Cash Flow | 11.28 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|